BioSpace News Archive

- 6 of 6 patients entered in the trial met the study’s primary endpoint of Clinical Cure at end of treatment - 2 of 2 patients achieved Sustained Clinical Cure, the study’s secondary endpoint of no recurrence of CDI at the 30-day follow-up - Ibezapolstat, a novel treatment for CDI, is the first of an entirely new class of antibiotics, DNA pol IIIC inhibitors, to enter clinical efficacy trials - C. difficile bacteria remain on CDC Urgent Threat list, highlighting nee

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the company’s results in greater detail. The conference call is being webcast and can be accessed from the Clovis Oncology website at www.clovison

Research Database to Quantify Impact of Potential COVID-19 Treatments, with Results from Over 500 Clinical Trials and Observational Studies Over the Next Three Months

Mr. Clancy brings significant strategic, financial and operational leadership experience in the biotechnology and pharmaceutical industry

Scientific Industries, Inc. (OTCQB:SCND), July 23, 2020 - Scientific Industries, Inc. announced the appointment of Reinhard Vogt to the Board of Directors and the resignation of Mr. James S. Segasture. Mr. John Moore, the Chairman of the Board, stated that the Company was extremely grateful for Mr. Segasture’s dedicated service to the Company as a Director since 1991 and wishes him well in his retirement.

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced changes in the composition of its board of directors that will take effect later this year. Two of the Company’s directors will be leaving the board and, effective September 1, 2020, two new directors will be joining. The new board members are Dr. Isabelle Buckle, Ph.D. and Dr. Catherine Larue,

Artio Medical, Inc. (Artio) today announced it has acquired Flow Forward Medical, Inc. (Flow Forward), a medical device company developing innovative methods for establishing and maintaining high-quality vascular access sites to improve outcomes for hemodialysis patients. This stock-for-stock merger transaction in which Flow Forward me

Phosplatin Therapeutics LLC , a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that the United States Patent and Trademark Office ( USPTO ) has issued US Patent No. 10,668,080, entitled: “Phosphaplatin Compounds as Therapeutics Agents for Treatment of Bone or Blood Cancers.” The granted claims are d

Lannett Company, Inc. announced that it has launched Mexiletine Hydrochloride Capsules 150 mg, 200 mg and 250 mg, a partnered product. Mexiletine Hydrochloride Capsules is the AB-rated generic equivalent to Mexitil® Capsules of Boehringer Ingelheim.

Second quarter revenues of $1.83 billion, down 6.4% from 2019